Ilyas Singeç joined NCATS in 2015 as the director of Stem Cell Translation Laboratory (SCTL) in the Division of Preclinical Innovation. Singeç translates stem cell discoveries into clinical applications, focusing on the development of new assays (tests), drugs and cell therapies. Learn about SCTL projects and resources.
Prior to joining NCATS, Singeç carried out postdoctoral work first at the National Institute of Neurological Disorders and Stroke and then at the Sanford Burnham Prebys Medical Discovery Institute in La Jolla, California, where he also served as staff scientist and director of cell reprogramming. Most recently, Singeç worked in the pharmaceutical and entrepreneurial industries.
Singeç earned his M.D. and Ph.D. summa cum laude in Germany at the Universities of Bonn and Freiburg, completing his residency in clinical neuropathology and neuroanatomy in Freiburg.
Using human induced pluripotent stem cells as a model system, Singeç is interested in industrial-scale cellular engineering for regenerative medicine, characterization of cell type identities and developmental states using integrated orthogonal methods and quantitative systems biology, and genetics-based disease modeling of neurological and psychiatric disorders.